Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition

On May8, 2017, Agile Therapeutics,Inc. (the Company) issued a
press release announcing its financial results for the first
quarter ended March31, 2017 and an update on the Companys
operations for the same period. The Company is furnishing a copy
of the press release, which is attached hereto as Exhibit99.1.

In accordance with General Instruction B.2 of Form8-K, the
information included in this Current Report on Form8-K (including
Exhibit99.1 hereto), shall not be deemed filed for the purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
into any filing made by the Company under the Exchange Act or
Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such a filing.

Item8.01.Other Events.

On May6, 2017, the Company announced the presentation of
additional results of its Phase 3 SECURE clinical trial of its
investigational low-dose combination hormone contraceptive patch,
Twirla (AG200-15). Anita Nelson, MD, Professor and Chair of
Obstetrics and Gynecology at the College of Osteopathic Medicine
of the Pacific, presented a summary of SECURE clinical trial
results, which included new data on the bleeding profile of
clinical trial subjects during a poster presentation at the 2017
Annual Clinical and Scientific Meeting of the American Congress
of Obstetricians and Gynecologists (ACOG) in San Diego,
California.

Dr.Nelson presented a summary of efficacy and safety results from
the Companys SECURE clinical trial, which were previously
reported in January2017. The poster presentation also reported
analyses on the bleeding profile, which demonstrated that
unscheduled bleeding/spotting days per month decreased from a
mean of 3.1 days in Cycle 1 to 1.6 days in Cycle 13. In addition,
scheduled bleeding/spotting remained consistent during all
cycles, with a reported mean of 3.1 to 3.7 days per month.
Dr.Nelson also discussed the role of study designs and
populations in contraceptive clinical trials.

Copies of the Companys press release and poster presentation are
attached hereto as Exhibit99.2 and 99.3, respectively, and are
hereby incorporated by reference herein.

Item 9.01.Financial Statements and
Exhibits.

(d) Exhibits.

About Agile Therapeutics, Inc. (NASDAQ:AGRX)

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Recent Trading Information

Agile Therapeutics, Inc. (NASDAQ:AGRX) closed its last trading session up +0.01 at 3.38 with 126,825 shares trading hands.